Adaptimmune’s debt financing deal; Tenaya to cut workers
2024-05-15
基因疗法细胞疗法
Plus, news about Brixton Biosciences, Merck KGaA, Medincell, CellProthera and GSK:
Adaptimmune inks up to $125M debt financing:
The
biotech
gets $25 million to start as it prepares for a commercial launch of its cell therapy. The money came through shortly after
Genentech axed a collaboration
that could’ve delivered $3 billion to Adaptimmune.
— Kyle LaHucik
Tenaya lays off 22% of its staff:
The biotech will
reduce
its workforce to save money for its gene therapies that are in the clinic for certain forms of cardiomyopathy. It had 140 full-time employees at the end of 2023,
according
to its most recently disclosed tally.
— Kyle LaHucik
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。